Biomodulation of fluorouracil in colorectal cancer

Cancer Investigation

Volumn 16, Issue 4, 1998, Pages 237-251

  Ardalan, Bach ^a,b   Luis, Raez ^a   Jaime, Merchan ^a   Franceschi, Dido ^b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; SPARFOSIC ACID; TRIMETREXATE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031944992     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039773     Document Type: Review

References (154)

1. Heidelberger C, Chandhari NK, Douglas H Jr: Fluorinated pyrimidines. A new class of tumor inhibiting compounds. Nature. 179:633-666, 1957.
2. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989.
3. Chu E, Takimoto CH: Anticancer drugs. In: Principles and Practice of Oncology, edited by VT De Vita Jr., S Hellman, SA Rosenberg. Philadelphia, JB Lippincott, 1993, pp 358-374.
4. Schuetz JD, Collins JM, Wallace HJ, et al: Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res 46:119-123, 1986.
5. Heggie GD, Sommadossi J-P, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47:2203-2206, 1987.
6. 14 in cancer patients. Cancer Res 23:49-66, 1963.
7. Coustere C, Mentre F, Sommadossi JP, et al. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 28:123-129, 1991.
8. McDermott BJ, Van der Berg HW, Murphy RF: Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 9:173-178, 1982.
9. Finan PJ, Chisholm EM, Giles GR. The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil in patients with colorectal carcinoma. Eur J Surg Oncol 13:349-353, 1987.
10. Diasio RB, Schuetz JD, Wallas HJ, Sommadossi. Dyhydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. Cancer Res 45:4900, 1985.
11. Grem J: 5-Fluoropyrimidines. In: Chabner B, Longo D: Cancer Chemotherapy and Biotherapy, 2nd ed. Philadelphia, Lippincott-Raven, 1996.
12. Haskell CM, Selch MT, Ramming KP: Colon and rectum. In: Cancer Treatment, edited by DM Haskell. Philadelphia, WB Sanders, 1990, pp 232-254.
13. Ansfield F, Schreder JM, Currieri AR: Five years experience with 5-fluorouracil. JAMA 181:295-299, 1962.
14. Hryniuk WM, Figueredo A, Goodyear M: Application of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987.
15. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34-40, 1977.
16. Ausman R, Caballero G, Quebbeman E: Long-term ambulatory continuous intravenous infusion of 5-fluorouracil for treatment of advanced adenocarcinomas. Proc Am Soc Clin Oncol 2:123, 1983 (abstract).
17. Belt RJ, Davidner ML, Myron MC, et al: Continuous low dose 5-fluorouracil (5-FU) for adenocarcinoma: Confirmation of activity. Proc Am Soc Clin Oncol 4:90, 1985 (abstract).
18. Benedetto P, Borgos M, Morillo G, et al: Chronic continuous infusion of 5-fluorouracil (CCI-FU) in previously untreated patients (pts) with measurable metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 5:92, 1986 (abstract).
19. Lokich JJ: Colorectal cancer. In: Cancer Chemotherapy by Infusion, edited by JJ Lokich. Chicago, Precept, 1987, pp 291-303.
20. Hansen R, Quebbeman E, Auman, et al: Continuous 5-fluorouracil (5-FU) infusion in colorectal cancer. Update of the MRC experience. Proc Am Soc Clin Oncol 6:80, 1987 (abstract).
21. 2/d continuous 5-FU. Proc Am Soc Clin Oncol 6:74, 1987 (abstract).
22. Wade JL, Herbst, Greenburgh A: Prolonged venous infusion (PVI) of 5-fluorouracil (5-FU) for metastatic colon cancer (MCC) - A follow up report. Proc Am Soc Clin Oncol 7:94, 1988 (abstract).
23. Schilky RL, Perry MC, Citron ML: High dose 5-fluorouracil (5-FU) therapy for advanced gastrointestinal (GI) malignancy. Proc Am Soc Clin Oncol 7:102, 1988 (abstract).
24. Kuo S, Finck S, Cho J, et al: Continuous ambulatory infusional 5-fluorouracil (5-FU) chemotherapy in advanced colorectal cancer: A single institutional retrospective study. Proc Am Soc Clin Oncol 8:126, 1989 (abstract).
25. Diaz-Rubio E, Aranda E, Martin M, et al: Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 26:727-729, 1990.
26. Rougier P, Ammarguellat H, Ghosn M, et al: Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. Oncology 49:35-39, 1992.
27. Seifert P, Baker LH, Reed ML, et al: Comparison of continuous infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975.
28. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989.
29. Weinemann B, Shah A, Fields A, et al: A randomized trial of continuous systemic infusion (CSI) vs. bolus therapy (B) with 5-fluorouracil (5FU) in metastatic measurable colorectal cancer (MCC). Am J Clin Oncol 15:518-523, 1992 (abstract).
30. Lokich JJ, Moore C: Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798-800, 1984.
31. Fiskus J: The effect of two methods of delivery of 5-fluorouracil on quality of life. Oncol Nurs Forum 14(Suppl 2): 122, 1987.
32. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil (5-FU) and its modulation in advanced colorectal cancer: A Southwest Oncology Group (SWOG) study. J Clin Oncol 13:1303-1311, 1995.
33. O'Dwyer PJ, Ryan LM, Valone JD, et al: Phase III trial of biochemical modulation of 5-FU by IV or oral leucovorin or by Interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 15:207, 1996 (abstract).
34. Baccanari DP, Davis S, Knick VC, et al: 5-Ethynyluracil: A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068, 1993.
35. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 54:1507-1510, 1994.
36. Spector T, Cao S, Rustum YM, et al: Attenuation of the antitumor activity of 5-fluorouracil by R-5-fluoro-5,6-dihydrouracil. Cancer Res 55:1239-1241, 1995.
37. Kemeny N: Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 3:190-214, 1987.
38. Bruckner H, Cohen J: MTX/5-FU trials in gastrointestinal and other cancers. Semin Oncol 10:32-39, 1983.
39. Marsh JC, Bertino JR, Rome LS, et al: Sequential methotrexate, 5-fluorouracil and leucovorin in metastatic colorectal cancer: A controlled comparison of two intervals between drug administration. Proc Am Soc Clin Oncol 8:103, 1989 (abstract).
40. Cadman E, Heimer R, Benz C: The influence of methotrexate pretreatment of 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256:1695-1704, 1981.
41. Cadman E, Davis L, Heimer R: Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 205:1135, 1979.
42. Allegra CJ, Chabner BA, Jolivet J: Enhanced inhibition of thymidylate synthase by methotrexate poly glutamates. J Biol Chem 230:9720, 1986.
43. Bertino JR, Mini E, Fernandes DJ: Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy. Semin Oncol 10(Suppl 2):2, 1983.
44. Benz C, Tillis T, Tattelman E, Cadman E: Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42:2081, 1982.
45. Benz C, Schoenberg M, Choti M: Schedule dependent cytotoxicity of methotrexate and 5-FU in human colon and breast tumor cells. J Clin Invest 66:1162-1165, 1980.
46. Bertino JR, Sawixki WL, Lindquist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37:327-328, 1977.
47. Mini E, Bertino JR: Time and dose relationships for methotrexate, fluorouracil and combinations of these drugs for maximum cell kill in human CCRF-CEM cells. Proc Am Assoc Cancer Res 23:181, 1982 (abstract).
48. 19sF nuclear magnetic resonance spectroscopy. Cancer Res 51:5806, 1991.
49. Sawyer RC, Stolfi RL, Martin DS, Balis ME: Inhibition by methotrexate of the stable incorporation of 5-FU into murine bone marrow DNA. Biochem Pharmacol 38:2305, 1989.
50. McSheehy PMJ, Prior MJ, Griffiths JR: Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat walker carcinosarcoma following methotrexate pre-treatment: A F-MRS study in vivo. Br J Cancer 65:369, 1992.
51. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371, 1991.
52. Plokin D, Ray M, Chien P: Sequential methotrexate-5-fluorouracil in advanced breast and colorectal cancer: A non-randomized pilot study. Proc Am Soc Clin Oncol 7:25, 1988 (abstract).
53. De Marco LC, Arena F, Desner M, et al: Low dose leucovorin and 5-FU modulation with prior methotrexate (L-FUSE-ME) for metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 7:104, 1988 (abstract).
54. Sierra R, Colman L, White D, et al: Sequential therapy with methotrexate and infusional 5-FU in advanced colorectal cancer. Proc Am Soc Clin Oncol 7:105, 1988 (abstract).
55. Heim ME, Schuster D, Fletchtner H, et al: Sequential high-dose methotrexate. 5-fluorouracil and folinic does not improve responses in advanced colorectal cancer. Onkologie 12:161-163, 1989.
56. Richards F II, Capizi RL, Muss H, et al: 5-fluorouracil (5-FU), high dose folinic acid and methotrexate for advanced colorectal cancer. A phase II trial of the Piedmont Oncology Association. Proc Am Soc Clin Oncol 8:101, 1989 (abstract).
57. Ajani JA, Kanojia MD, Bedikian AV: High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol 12:335-338, 1989.
58. Balaban E, Frenkel E, Penman P, et al: Sequential methotrexate, high-dose folinic acid, and 5-fluorouracil for advanced colorectal carcinoma: A phase II trial of the Texas Regional Oncology Group. Proc Am Soc Clin Oncol 9:122, 1990 (abstract).
59. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 7:1437-1446, 1989.
60. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989.
61. Macchiavelli M, Leone BA, Romero A, et al: Advanced colorectal carcinoma (CRC): A prospective randomized trial of sequential methotrexate (MTX)-5-fluorouracil (5-FU) vs. 5-FU alone. Proc Am Soc Clin Oncol 9:102, 1990 (abstract).
62. Kemeny N, Reichman B, Geller N, et al: Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma. Am J Clin Oncol 11:66-72, 1988.
63. Hermann R, Knuth A, Kleeberg U, et al: Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. Ann Oncol 3:539-543, 1992.
64. O'Connell MJ, Poon MA, Wieand HS: Biochemical modulation of 5-fluorouracil (5-FU) with leucovorin (LV): Confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 9:A408, 1990) (abstract.
65. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987.
66. Polyzos A, Tsavaris N, Giannopoulous A, et al. Biochemical modulation of fluorouracil: Comparison of methotrexate, folinic acid and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol 38:292-297, 1996.
67. O'Dwyer PJ, DeLap RJ, et al. Trimetrexate: Clinical development of a nonclassical antifolate. Natl Cancer Inst Monogr 5:105-109, 1987.
68. Kamen BA, Cashmore AR, Dreyers RN, et al: Uptake and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resis- tant leukemia cells in vitro. Biochem Pharmacol 33:1697-1699, 1984.
69. Jackson RC, Froy DW, et al: Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 22:187-206, 1984.
70. Romanini A, Li WW, Colofiore JR, Bertino JR: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 84:1033-1038, 1992.
71. Conti JA, Kemeny N, Seiter K, et al: Trial of sequential trimetrexate, fluorouracil and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695-700, 1994.
72. Blanke C, Kasimis B, Schein P: A phase II trial of trimetrexate, 5-fluorouracil and leucovorin in patients with unresectable or metastatic colon cancer. Proc Am Soc Clin Oncol 15:433, 1996 (abstract).
73. Silgals RM, Ahlgren JD, Neefe JR, et al: A phase II trial of high dose intravenous interferon alpha 2 in advanced colorectal cancer. Cancer 54:2257-2261, 1984.
74. Krown SE, Mintzer D, Cunningham-Rundles S, et al: High-dose human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses. Cancer Treat Rep. 71:39-45, 1987.
75. Lillis PK, Brown T, Beougher K, et al: A phase II trial of recombinant beta interferon (Betaseron) in advanced colorectal cancer. Proc Am Soc Clin Oncol. 6:86, 1987 (abstract).
76. Brown T, Fleming T, Goodman P, Macdonald J: Randomized phase n trial of recombinant gamma interferon administered on two schedules in advanced colorectal cancer: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol. 8:124, 1989 (abstract).
77. Elias L, Crissman HA: Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48:4868-4873, 1988.
78. Wadler S, Schwanz EL, Goldman M, et al: Preclinical and clinical studies of 5-fluorouracil and recombinant alpha-2a-interferon against gastrointestinal malignancies. Clin Res 36:803A, 1988 (abstract).
79. Namba M, Myoshi T, Kanamori T, et al: Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Gann 73:819-824, 1982.
80. Welander CE, Morgan TM, Homesly HD, et al: Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35:721-729, 1985.
81. Chu E, Sinn S, Boarman D, et al: Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50:5834-5840, 1990.
82. Pazdur R: Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms. Br J Hematol 79(Suppl l):56-59, 1991.
83. Wadler S, Lembersky B, Kirkwood J, et al: Phase II trial of fluorouracil (5FU) and recombinant alpha-2 interferon (IFN) in patients (pts) with advanced colorectal cancer: An Eastern Cooperative Oncology Group (ECOG) study. J Clin Oncol 9:1806-1810, 1991.
84. Grem J, McAtee N, Murphy RF, et al: Phase I study of interferon alpha-2a (INF-A), in combination with 5-fluorouracil (5-FU) and high dose leucovorin (LV) in metastatic gastrointestinal carcinoma. J Clin Oncol 9:1811, 1991.
85. Wadler S, Wiemik PH: Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 17:16-21, 1990.
86. Kemeny NE, Schneider A, Martin DS: Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and undine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. Cancer Invest 8:263-264, 1990.
87. Einhorn S, Blomgren H, Strander H: Interferon and spontaneous cytotoxicity in man. Acta Med Scand 204:477-483, 1978.
88. Hunddlestone JR, Merigan TO, Okistone MBA: Induction and kinetics of natural killers in humans following interferon therapy. Nature 282:417-419, 1979.
89. Gewert DR, Moore, Clemens MJ: Inhibition of cell division by interferons. The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells. Biochem J 214:983-990, 1983.
90. Kase S, Kubota T, Watanabe M, et al: Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue. Anticancer Res 14 (3A):1155-1159, 1994.
91. Wadler S, Goldman M, Lyver A, et al: Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 50:2056-2059, 1990.
92. Wadler S, Schwartz EL, Godman M, et al. Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989.
93. Pavlidis N, Nicolaides C, Athanassiadis A, et al: Phase II study of 5-fluorouracil and interferon gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study. Oncology 53:159-162, 1996.
94. Pazdur R, Ajani JA, Patt YZ, et al: Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8:2027-2031, 1990.
95. Fomasiero A, Daniele O, Ghiotto C, et al: Alpha 2 interferon and 5-fluorouracil in advanced colorectal cancer. Tumori 76:385-388, 1990.
96. Huberman M, McClay E, Atkins M, et al: Phase II trial of 5 fluorouracil (5FU) and recombinant interferon-alpha-2a (INF) in advanced colorectal cancer. Proc Am Soc Clin Oncol 10:153, 1991 (abstract).
97. Douillard JY, Leborgne J, Danielou JY, et al: Phase II trial of 5-fluorouracil (5FU) and recombinant alpha interferon (RAIFN) (Intron AR) in metastatic, previously untreated colorectal cancer (CRC). Proc Am Soc Clin Oncol 10:139, 1991 (abstract).
98. Pazdur, Ajani JA, Patt YZ, et al: Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 71:1214-1218, 1993.
99. Pazdur R, Abbruzzese J, Faintuch J, et al: Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 9:117, 1990 (abstract).
100. Huberman M, Bering H, Tessitore J, et al: 5-fluorouracil plus recombinant alpha interferon (Roferon A) in advanced colorectal cancer. Proc Am Soc Clin Oncol 9:116, 1990 (abstract).
101. Kemeny N, Kelsen D, Derby S, et al: Combination of 5-fluorouracil plus recombinant alpha interferon in advanced colorectal cancer. Proc Am Soc Clin Oncol 9:109, 1990.
102. Kocha W. The Corfu-A Collaborative Group: 5-Fluorouracil (5-FU) plus interferon alfa-2a (Roferon-A) versus 5-fluorouracil plus leucovorin (LV) in metastatic colorectal cancer-Results of a multicenter multinational phase III study. Proc Am Soc Clin Oncol 12:193, 1993 (abstract).
103. Hill M, Norman A, Cunningham D, et al: Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995.
104. York M, Greco FA, Figlin RA, et al: A randomized phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 12:200, 1993 (abstract).
105. Kreuser ED, Matthias M, Boewer C, et al: Double modulation of 5-fluorouracil with interferon a-2b and folinic acid in metastatic colorectal cancer. Proc Am Soc Clin Oncol 10:150, 1991 (abstract).
106. Labianca R, Pancera G, Luporini A, et al: Double modulation of 5-fluorouracil (5FU) with a2b interferon (IFN) and folinic acid (FA) in advanced colorectal cancer. Ann Oncol 1(Suppl):92, 1990
107. Punt CJA, De Mulder PHM, Burghouts JTM: A phase I-II study of high dose 5-fluorouracil (5FU), leucovorin (LV) and a-inter- feron (aINF) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 10:150, 1991 (abstract).
108. Inoshita G, Yalavarthi P, Murthy S, et al: Phase I trial of 5FU, leucovorin (LV) and rHuINF-a2a in metastatic colorectal cancer (CR Ca). Proc Am Soc Clin Oncol 10:152, 1991 (abstract).
109. Kohne-Wompner CH, Schmoll HJ, Hiddemann H, et al: 5-fluorouracil (FU), leucovorin (LV), alpha-2b interferon (INF) in advanced colorectal cancer (CC): A phase I/II study. Proc Am Soc Clin Oncol 10:159, 1991 (abstract).
110. Schuller J, Czejka M, Miksche M: Influence of interferon a 2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil. Proc Am Soc Clin Oncol 10:98, 1991 (abstract).
111. Grem JL, Jordan E, Robson ME, Binder RA, et al: Phase II study of fluorouracil, leucovorin and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 11: 1737-1745, 1993.
112. Sinnigie HA: Phase I-II study of the addition of alpha-2a interferon to 5-FU leucovorin-pharmacokinetic interaction of alpha-2A interferon and leucovorin. Eur J Cancer 29A: 1715-1720, 1993.
113. Mini E, Moroson BA, Bertino JR: Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: Enhancement by leucovorin. Cancer Treat Rep 71:381-389, 1987.
114. Grem J: 5-Fluoropyrimidines. In: Cancer Chemotherapy and Biotherapy, 2nd ed, edited by B Chabner, D Longo. Philadelphia, Lippincot-Raven, 1996.
115. Houghton JA, Williams LG, Siebold SN, et al: Relationship between dose rate of [6RS] leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylene-tetrahydrofolate and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50:3493-3502, 1990.
116. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986.
117. Laufman LR, Krzeczowski K, Roach R, et al: Leucovorin plus 5-fluorouracil: An effective treatment for metastatic colon cancer. J Clin Oncol 5:1394-1400, 1987.
118. DeGramont A, Krulik M, Cady J, et al: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24:1499-1503, 1988.
119. Di Costanzo F, Bartolucci R, Padalino D, et al: High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. Cancer Invest 6:133-138, 1988.
120. Laufman LR, Brenckman WDJ, Stydnicki KA, et al: Clinical experience with leucovorin and 5-fluorouracil. Cancer 63:1031-1035, 1989.
121. Fried G, Tsalk M, Stein M, et al: 5-Fluorouracil and low dose leucovorin in metastatic colorectal cancer. A pilot study. Cancer Chemother Pharmacol 35:437-140, 1995.
122. Abad A, Garcia P, Gravalos C, et al: Sequential methotrexate, 5-fluorouracil and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multiinstitutional randomized trial. Cancer 75:1238-1244, 1995.
123. Erlichman C, Fine S, Kerr I, et al: A phase II trial of 5-FU and 1-leucovorin in patients with metastatic colorectal cancer. Am J Clin Oncol 19:26-31, 1996.
124. Recchia F, Nuzzo A, Calli A, et al: Randomized trial of 5-FU and high dose folinic acid with or without alpha-2β interferon in advanced colorectal cancer. Am J Clin Oncol 19(3):301-304, 1996.
125. Advanced Colorectal Meta-Analysis project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
126. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988.
127. Labianca R, Pancera G: A randomized study of intravenous fluorouracil + folinic acid (FA) in advanced metastatic colorectal cancer (AMC). Proc Am Soc Clin Oncol 8:118, 1989 (abstract).
128. Petrelli N, Douglass HOJ, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gatrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989.
129. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990.
130. Brenckman WD, Laufman LR, Adamkiewicz MA, et al: Is fluorouracil (FU) plus placebo (P) as effective as equitoxic doses of FU plus high dose oral leucovorin (LV) in colorectal cancer? Proc Am Soc Clin Oncol 9:109, 1990 (abstract).
131. Di Costanzo F, Bartolucci R, Calabresi F, et al: Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 3:371-376, 1992.
132. Loffler TM, Korsten FW, Reis HE, et al: Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma. Dtsch Med Wochenschr 117:1007-1013, 1992.
133. Nobile MT, Rosso R, Sertoli MR, et al: Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 28A: 1823-1827, 1992.
134. Steinke B, Gunther E, Hirschmann WD, et al: Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer-preliminary results of a randomized trial. Semin Oncol 19(2 Suppl 3): 141-147, 1992.
135. Poon MA, O'Connel MJ, Vieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967, 1991.
136. Houghton PJ, Rahman A, Will CL, et al: Mutation of the thymidy late synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates. Cancer Res 52:558, 1992.
137. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053-1058, 1988.
138. Ardalan B, Chua L, Er-ming T, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991.
139. Ardalan B, Hussein A, Skaver L, et al: Chemotherapy (C) of advanced carcinoma (CA) with 5-fIuorouracil (FU) with leucovorin (LV). Proc Am Soc Clin Oncol 8:116, 1989 (abstract).
140. Ardalan B, Glazer RI, Kensler TW, et al: Synergistic effect of fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in a human mammary carcinoma. Biochem Pharmacol 30:2045-2049, 1981.
141. Spiegelman S, Sawyer RR, Naya R, et al: Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA metabolic modulation. Proc Natl Acad Sci USA 77:4966-4970, 1980.
142. Martin DS, Stolfi RL, Sawyer RC, et al: Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res 43:2317-2321, 1983.
143. Ardalan B, Villacorte D, Heck D, Corbett T: Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinoma. Biochem Pharmacol 31:1989-1992, 1982.
144. Chi-Ming L, Donehower C, Chabner B: Biochemical interactions between N-(phosphonacetyl)-L aspartate and 5-fluorouracil. Mol Pharmacol 21:224-230, 1982.
145. Bedikian AY, Stroehlein JR, Karlin DA, et al: Chemotherapy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat Rep 65:747-753, 1981.
146. O'Connell MJ, Powis G, Rubin J, et al: Pilot study of PALA and 5-FU in patients with advanced cancer. Cancer Treat Rep 66:331-334, 1981.
147. Martin DS, Stolfi RL, Sawyer RC, et al: Application of biochem ical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 69:421-423, 1985.
148. Muggia FM, Camacho FJ, Kaplan BH, et al: Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer. Cancer Treat Rep 71:253-256, 1987.
149. Buroker TR, Moerte CG, Fleming TR, et al: A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3:1624-1631, 1985.
150. Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B: Biochemistry and clinical activity of PALA: A review. Cancer Res 48:4441-4454, 1988.
151. Casper ES, Vale K, Williams LJ, et al: Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res 43:2324-2329, 1983.
152. O'Dwyer PJ, Paul AR, Walczak J, et al: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 6:1053-1058, 1988.
153. Ardalan B, Sridhar KS, Benedetto P, et al: A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 68:1242-1246, 1991.
154. Martin DS: Biochemical modulation: perspectives and objectives. In: Proceedings of the Eighth Bristol-Myers Symposium on Cancer Research. New Avenues in Developmental Cancer Chemotherapy, edited by KR Harrap, TA Connors. London, Academic Press, 1987, pp 113-162.